Vital Therapies reported $-21414000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Biomarin Pharmaceutical BMRN:US $ 56.67M 96.56M
Dynavax Technologies DVAX:US $ 32.46M 49.7M
Enanta Pharmaceuticals ENTA:US $ -33.02M 3.4M
Epizyme EPZM:US $ -49.63M 0.33M
Insmed INSM:US $ -98173000 1.78M
Intercept Pharmaceuticals ICPT:US $ -9.9M 10.55M
Mirati Therapeutics MRTX:US $ -183.59M 12.92M
Orasure Technologies OSUR:US $ -12.33M 6.18M
Quidel QDEL:US $ 640.48M 241.54M
Regulus Therapeutics RGLS:US $ -6.54M 0.28M
Revance Therapeutics RVNC:US $ -56.84M 0.66M
Ultragenyx Pharmaceutical RARE:US $ -132.54M 33.51M
United Therapeutics UTHR:US $ 300.5M 117.1M
Vital Therapies VTL:US $ -21.41M 0.26M
Xoma XOMA:US $ -2063000 32.43M